Signal integration of chimeric antigen receptors and the inhibitory Programmed cell death protein 1 receptor

嵌合抗原受体和抑制性程序性细胞死亡蛋白1受体的信号整合

• 批准号: nhmrc : GNT1163814
• 金额: $ 48.68万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/signal-integration-chimeric-1-receptor/1379319
• 关键词: Signal; integration; chimeric; antigen; receptors

T cells recognise and kill infected or cancerous cells and tolerate healthy tissue by integrating information from activating and inhibitory surface receptors. Activating receptors engineered to target cancer show great promise as therapies but their sensitivity to endogenous inhibitory receptors, which cancers exploit, is unknown. We will use powerful biochemical and microscopy techniques to probe this question. The results will inform the design of more effective anti-cancer therapeutics.

T细胞通过整合来自激活和抑制表面受体的信息，识别并杀死感染或癌细胞，并耐受健康组织。针对癌症而设计的活化受体作为治疗方法显示出巨大的前景，但它们对癌症利用的内源性抑制受体的敏感性尚不清楚。我们将使用强大的生物化学和显微镜技术来探索这个问题。这些结果将为设计更有效的抗癌疗法提供信息。